Literature DB >> 9442958

Iodine-131 MIBG imaging in multiple endocrine neoplasia type 2B.

Y Yamamoto1, Y Isobe, Y Nishiyama, H Takashima, M Ohkawa, M Kihara, K Matsusaka, A Miyauchi, S Kobayashi, M Tanabe.   

Abstract

A 16-year-old boy had a swollen neck that was a result of multiple endocrine neoplasia Type 2B (MEN 2B). CT revealed bilateral thyroid tumors, swelling of right cervical lymph nodes, and slight enlargement of the right adrenal gland. I-131 metaiodobenzylguanidine (MIBG) scintigraphy demonstrated increased uptake in the right adrenal gland and the left thyroid tumor, but no abnormal uptake in the right thyroid tumor and the right cervical lymph nodes. Postoperative pathologic findings were consistent with the diagnosis of right adrenal medullary hyperplasia, which is a precursor of pheochromocytoma. In patients with MEN 2B, I-131 MIBG scintigraphy in conjunction with CT of the adrenal glands should be performed to determine the disease stage of the adrenal medullae. In the cervical region, the diagnosis was medullary thyroid carcinoma (MTC) in both thyroid tumors and metastases in the right cervical lymph nodes. The right MTC was more aggressive than the left MTC. It is interesting that not all sites of known MTC take up I-131 MIBG to the same degree.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442958     DOI: 10.1097/00003072-199801000-00005

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  2 in total

1.  Multi-step approach in a complex case of Cushing's syndrome and medullary thyroid carcinoma.

Authors:  G Parenti; R Nassi; S Silvestri; S Bianchi; A Valeri; G Manca; S Mangiafico; F Ammannati; M Serio; M Mannelli; A Peri
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

2.  Diagnosis and treatment of adrenal medullary hyperplasia: experience from 12 cases.

Authors:  Lu Yang; Liang Gao; Xiao Lv; Shengqiang Qian; Siyuan Bu; Qiang Wei; Jiuhong Yuan; Tianyong Fan
Journal:  Int J Endocrinol       Date:  2014-08-27       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.